Efficacy results of a trial of a herpes simplex vaccine. - Wikidata - wikimedia - TriplyDB

Efficacy results of a trial of a herpes simplex vaccine.

Efficacy results of a trial of a herpes simplex vaccine.

http://www.wikidata.org/entity/Q35780697

about

Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown Understanding natural herpes simplex virus immunity to inform next-generation vaccine design Optimal management of genital herpes: current perspectives Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions Immune response to HHV-6 and implications for immunotherapy Multipurpose prevention technologies: the future of HIV and STI protection Maternal immunization Recent advances in vaccine development for herpes simplex virus types I and II Immune regulation of human herpesviruses and its implications for human transplantation The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine Local CD4 and CD8 T-cell reactivity to HSV-1 antigens documents broad viral protein expression and immune competence in latently infected human trigeminal ganglia Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital Mucosa Incidence of herpes simplex virus type 2 infections in Africa: a systematic review The scarlet H IgG in cervicovaginal mucus traps HSV and prevents vaginal herpes infections The herpevac trial for women: Sequence analysis of glycoproteins from viruses obtained from infected subjects.Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women A herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigs Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging.The murine intravaginal HSV-2 challenge model for investigation of DNA vaccines.Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus 2 glycoprotein D An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge Current status and prospects for development of an HSV vaccine Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.Prophylactic and therapeutic modulation of innate and adaptive immunity against mucosal infection of herpes simplex virus Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivo HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression.Antiherpes simplex virus type 2 activity of the antimicrobial peptide subtilosin Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2.Update on herpes virus infections of the nervous system.A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.Prospects and perspectives for development of a vaccine against herpes simplex virus infections.Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity Inhibition of HSV-1 Replication by Gene Editing Strategy Intravaginal Zinc Oxide Tetrapod Nanoparticles as Novel Immunoprotective Agents against Genital Herpes.An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs.Anti-glycoprotein g antibodies of herpes simplex virus 2 contribute to complete protection after vaccination in mice and induce antibody-dependent cellular cytotoxicity and complement-mediated cytolysis Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans

P2860

Q21296712-3BFFA70D-ACF7-4DDB-AD6B-E2E2E5260CE7 Q26741484-C0CEE40C-080A-4B1F-BEA3-0003F1485430 Q26746041-0202DA00-E02D-4AC1-AA8A-C6E161AA569A Q26823594-45EFAA1D-66E3-4D1B-83E1-C39B8EEDDEE7 Q26827409-9CF61FCB-107D-41A3-B506-7A35C146003A Q26827796-23528466-6663-401D-AFB6-3A55F755225B Q26853746-792EC344-3B87-425F-9320-15C257E410D7 Q26859623-652D024B-F84D-46AA-818E-3A4438002722 Q26992146-E152C1D6-4629-4585-9C24-A24FE0EF4A47 Q27021292-661D0A08-4468-42D5-B422-CF0983864DA5 Q27333997-2E83FB98-0BF7-4F39-97F0-239B579AFF19 Q27347896-B8049D6B-0C44-457E-B37E-BB4688722016 Q27690876-88D0B360-FB75-49B5-9716-E2DB7916E488 Q28114465-A787E208-3DDE-497B-9768-EE4F7095D9D8 Q30585914-9FCCC46B-6CA9-4418-880F-AC05B9014950 Q33610941-19167D84-F789-4B47-B24F-12D8468DE4B1 Q33663463-DD823D46-C8DF-4044-BCF5-6DBC8B491336 Q33825931-111B6FBF-566D-4A9E-8732-BC97E57D7CA4 Q33834821-AD95C6AC-5BA4-4B81-B6E4-BE63A4824A4A Q33856067-3398BE5A-2711-40F8-8637-A02BC9211911 Q33900262-67B11E7B-39D8-4EF9-AD72-A277010E9325 Q33916162-F89F6504-6037-4783-AF30-FE7523274830 Q33931016-BC01E168-3678-4FD9-926B-D835E47F2171 Q34057952-F830F38A-A6E0-4451-9680-8E7070370A21 Q34105712-952DFA1C-7738-460D-8381-71F95EBCD212 Q34229689-BF73FA4E-98A7-484F-9CC0-CFFDE6CF3650 Q34331569-6C796504-4CBC-4434-852B-6A184A3AB6E9 Q34333815-493D770E-2554-42FD-B295-0F80081E7DDC Q34345122-1C92F6F1-817F-4C18-AC80-1E709CF5ACB2 Q34350019-EAFC56CE-3B2E-4BC4-86A6-3AA8FB6906F6 Q34379006-9275A284-7F79-4053-B7FB-0D11BAD3FF09 Q34414463-C1F99641-1B47-483A-A234-431817FE2FD3 Q34431547-5596BD17-3C89-4063-968C-43AB22EFA0D6 Q34447379-A1E1527B-A2D3-4F80-81F2-80CBDDBDF1E9 Q34520389-C38C4749-6712-4912-86A2-7C8ECFFCFEF0 Q34521509-1DA217B1-3843-4E54-B7C7-01419D79ADC9 Q34526716-F49DA6EB-768C-4BF5-A6D1-69AC67948707 Q34549656-2889662C-8D96-470F-8B83-6CC05E47FC7B Q34580831-30943678-6443-4DA8-812C-8ED6929514CB Q34593833-F1E4FA0B-B02C-41F2-8AF8-CDA8EF763FF5

P2860

Efficacy results of a trial of a herpes simplex vaccine.

http://www.wikidata.org/entity/Q35780697

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Efficacy results of a trial of a herpes simplex vaccine.

@ast

Efficacy results of a trial of a herpes simplex vaccine.

@en

type

label

Efficacy results of a trial of a herpes simplex vaccine.

@ast

Efficacy results of a trial of a herpes simplex vaccine.

@en

prefLabel

Efficacy results of a trial of a herpes simplex vaccine.

@ast

Efficacy results of a trial of a herpes simplex vaccine.

@en

P1433

Q35780697-61D8FDC2-5ECE-4D9D-8DDB-1B382ACA76DF

P1476

Q35780697-E40873F7-E0E9-478B-83E5-C19083EFC385

P2093

Q35780697-0B786849-07E6-49A8-BD62-2B7DDB8A1F6D

Q35780697-12DB6D7E-2544-422A-9D68-666F21FF37A3

Q35780697-2A9D0B68-893C-4189-8259-AAE5AFE8A8B3

Q35780697-2C81B879-73B9-45F7-9E73-72E9C3D767FD

Q35780697-3A9E5465-C2DA-4987-9A1F-E182F1D4E851

Q35780697-689FE391-1A72-41A7-B78E-F66DF1AB31AB

Q35780697-6E5302B9-6448-43A8-B78A-1AFA8A762EF0

Q35780697-71C3C688-C2C0-4017-B6FB-7CD721A0D7A8

Q35780697-8623E061-657D-4BE3-BD2B-197A63E95B74

Q35780697-88767DD7-E857-462C-AE3F-15A768EC268E

P2860

Q35780697-0828AB58-2068-45A2-8936-90C53019F07F

Q35780697-29F94F29-EF6F-4AE5-A749-4E353B80BDF2

Q35780697-41A621EF-E37F-4F24-A9A8-1319FE9FC45A

Q35780697-4BD8D9CD-FE52-4BDF-A8D1-402728713B6D

Q35780697-86D3A05B-8BD0-4C30-A13C-ED5DE3545ABD

Q35780697-894EADD7-AB99-40DB-A798-C40DB647E403

Q35780697-8C1258EE-2F83-4D6A-86A9-EEE844275CD9

Q35780697-952647CE-FAA3-4C89-AD18-1D44263FE94E

Q35780697-95754512-C141-4119-862F-0B36D03F02FD

Q35780697-A8B33D2A-30C8-499D-871D-4B98CD3658ED

P304

Q35780697-92A703F8-8111-4056-B996-4AF56D887451

P31

Q35780697-4F90B874-345F-4291-8A83-3C1AE25668C6

P356

Q35780697-4BCFEBB0-A430-453E-B495-7BFFAE460C5A

P407

Q35780697-8F08492D-C76F-4E7C-BCE7-3EF5599A67DE

P433

Q35780697-254D0F20-69F3-4ABB-84E6-8F5B410930F0

P478

Q35780697-F7840F1A-FBCF-4F24-9102-D3344E6F06CE

P50

Q35780697-006F86A7-31F4-43B9-B074-E94706F72588

P577

Q35780697-FE63ACAB-7AD8-47C5-AA5C-FCF7148D1732

P698

Q35780697-EDA7AE1F-D4BF-4748-8CA8-DDF33C202421

P932

Q35780697-9EF018FD-31EF-48E3-A139-6041C5F4A86F

P356

P1433

The New England Journal of Medicine

P1476

Efficacy results of a trial of a herpes simplex vaccine.

@en

P2093

Abbie Stokes-Riner

http://www.w3.org/2001/XMLSchema#string

Carolyn D Deal

http://www.w3.org/2001/XMLSchema#string

David I Bernstein

http://www.w3.org/2001/XMLSchema#string

Gary Dubin

http://www.w3.org/2001/XMLSchema#string

Herpevac Trial for Women

http://www.w3.org/2001/XMLSchema#string

Iris Gorfinkel

http://www.w3.org/2001/XMLSchema#string

Jack T Stapleton

http://www.w3.org/2001/XMLSchema#string

Joann M Schulte

http://www.w3.org/2001/XMLSchema#string

Marian G Ewell

http://www.w3.org/2001/XMLSchema#string

Myron J Levin

http://www.w3.org/2001/XMLSchema#string

P2860

Maternal and neonatal herpes simplex virus infections

Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population based survey

Herpes simplex virus type 1 is the prevailing cause of genital herpes in the Tel Aviv area, Israel.

Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students.

Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.

The burden of infection with HSV-1 and HSV-2 in England and Wales: implications for the changing epidemiology of genital herpes.

Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa

Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992-2006.

Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection.

Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2.

P304

34-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1103151

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

366

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22216840

http://www.w3.org/2001/XMLSchema#string

P932

3287348

http://www.w3.org/2001/XMLSchema#string